Cefadroxyl Vatchem (Granules) Instructions for Use
Marketing Authorization Holder
Waltham-Pharmacy, LLC (Russia)
ATC Code
J01DB05 (Cefadroxil)
Active Substance
Cefadroxil (Rec.INN registered by WHO)
Dosage Form
| Cefadroxil Vatchem | Granules for the preparation of an oral suspension 250 mg/5 ml of the prepared susp.: bottle 45 g |
Dosage Form, Packaging, and Composition
Granules for the preparation of an oral suspension white or white with a yellowish tint.
| 5 ml of the prepared susp. | |
| Cefadroxil | 250 mg |
Excipients: saccharin, gum, magnesium stearate, colloidal silicon dioxide, titanium dioxide, peach and apricot flavor, talc, sucrose.
45 g – bottles (1) complete with a measuring spoon – cardboard packs.
Clinical-Pharmacological Group
First generation cephalosporin
Pharmacotherapeutic Group
Antibiotic-cephalosporin
Pharmacological Action
A first-generation broad-spectrum cephalosporin antibiotic for oral administration. It has a bactericidal effect.
It is active against gram-positive bacteria: Staphylococcus spp. (penicillinase-producing and non-producing strains), Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis; gram-negative bacteria: Shigella spp., Salmonella spp., Haemophilus influenzae, Escherichia coli, Klebsiella spp., some strains of Proteus spp.
Indications
Infectious and inflammatory diseases caused by microorganisms sensitive to cefadroxil, including: diseases of the urinary tract, upper and lower respiratory tract, skin, soft tissues, bones.
ICD codes
| ICD-10 code | Indication |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| M00 | Pyogenic arthritis |
| M86 | Osteomyelitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N41 | Inflammatory diseases of prostate |
| N70 | Salpingitis and oophoritis |
| N71 | Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess) |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| FA1Z | Infectious arthropathies, unspecified |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| GA01.Z | Inflammatory diseases of uterus, except cervix, unspecified |
| GA07.Z | Salpingitis and oophoritis, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
The dosage is set individually, taking into account the severity and localization of the infection, and the sensitivity of the pathogen. For oral administration in adults and children with a body weight over 40 kg, the average dose is 1-2 g/day in 1-2 doses. For children with a body weight less than 40 kg – 25-50 mg/kg/day (preferably in the form of a suspension) in 1-2 doses. The course of treatment is 7-14 days. The minimum duration of treatment for infectious and inflammatory diseases caused by group A beta-hemolytic streptococcus is 10 days.
For patients with impaired renal excretory function, the single dose is 500 mg, the intervals between doses are determined depending on the CC values: with CC 0-10 ml/min – 36 h; with CC 10-25 ml/min – 24 h; with CC 25-50 ml/min – 12 h.
Adverse Reactions
Allergic reactions are possible (urticaria, skin itching, eosinophilia; in isolated cases – angioedema, anaphylactic shock); rarely – nausea, vomiting, diarrhea, candidiasis, headache, dizziness; in some cases – changes in the peripheral blood picture (reversible leukopenia, neutropenia, thrombocytopenia).
Contraindications
Hypersensitivity to cephalosporins.
Use in Pregnancy and Lactation
Use during pregnancy and lactation (breastfeeding) is possible only in cases where the intended benefit to the mother outweighs the potential risk to the fetus or child.
Use in Renal Impairment
For patients with impaired renal excretory function, the single dose is 500 mg, the intervals between doses are determined depending on the CC values: with CC 0-10 ml/min – 36 h; with CC 10-25 ml/min – 24 h; with CC 25-50 ml/min – 12 h.
Pediatric Use
Use is possible according to the dosing regimen.
Special Precautions
In patients with hypersensitivity to penicillins, allergic reactions to cephalosporin antibiotics are possible.
Alcohol should not be consumed during treatment.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
OKI, sachets 80mg 2g, 12pcs
Belosalic, lotion solution for external use spray 100ml
Noopept, pills 10mg, 50pcs
Kagocel pills 12mg, 30pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Ingavirin capsules 90mg, 10pcs
Fenotropil pills 100mg, 60pcs
No-spa pills 40mg, 64pcs
Actovegin pills 200mg, 50pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Daivobet, ointment, 30g
Phenibut-Vertex pills 250mg, 20pcs
Cortexin, 10mg, 5ml, 10pcs
Picamilon pills 50mg, 60pcs 